{"nctId":"NCT04508309","briefTitle":"Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls","startDateStruct":{"date":"2021-03-15","type":"ACTUAL"},"conditions":["Cervical Cancer"],"count":1025,"armGroups":[{"label":"Cecolin® at 0 and 6 months","type":"EXPERIMENTAL","interventionNames":["Biological: Cecolin®"]},{"label":"Cecolin® at 0 and 12 months","type":"EXPERIMENTAL","interventionNames":["Biological: Cecolin®"]},{"label":"Cecolin® at 0 and 24 months","type":"EXPERIMENTAL","interventionNames":["Biological: Cecolin®"]},{"label":"Gardasil® at 0 and 6 months","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Gardasil®"]},{"label":"Gardasil® at 0 and Cecolin® at 24 months","type":"OTHER","interventionNames":["Biological: Cecolin®","Biological: Gardasil®"]}],"interventions":[{"name":"Cecolin®","otherNames":[]},{"name":"Gardasil®","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Healthy (determined by investigator's assessment following medical history and physical examination, laboratory evaluation could be performed at the investigator's discretion) female between the ages of 9 - 14 years (all inclusive) at time of enrollment\n2. Ability and willingness to provide parental consent and, if applicable based on local in-country regulations, participant assent\n3. Parent/Legally Acceptable Representative provides informed consent\n4. Anticipated ability and willingness to complete all study visits and evaluations\n5. Living within the catchment area of the study without plans to move during the conduct of the study\n\nExclusion Criteria:\n\n1. Presence of fever or acute disease on the day of vaccination (oral or axillary temperature ≥ 38˚ C)\n2. If participants have childbearing potential, must not be breastfeeding or confirmed pregnant\n3. Receipt of an investigational product within 30 days prior to randomization\n4. Receipt of blood and/or blood products (including immunoglobulin) 3 months prior to any dose of vaccination or blood sampling\n5. Receipt of a live virus vaccine (varicella virus containing vaccine, any measles, mumps, or rubella virus containing vaccine such as Measles, Mumps, and Rubella (MMR), or yellow fever vaccine but not including live attenuated influenza virus vaccine) 4 weeks prior and after each dose of HPV vaccine\n6. History of any physical, mental, or developmental disorder that may hinder a participant's ability to comply with the study requirements\n7. Any malignancy or confirmed or suspected immunodeficient condition such as HIV infection, based on medical history and physical examination\n8. Receipt of or history of receipt of any medications or treatments that affect the immune system\n9. Allergies to any components of the vaccine\n10. Current or former participation in HPV vaccine related research.\n11. Prior receipt of an investigational or licensed HPV vaccine\n12. Any other condition(s) that in the opinion of the investigator would jeopardize the safety or rights of a participant participating in the trial or would render the participant unable to comply with the protocol","healthyVolunteers":true,"sex":"FEMALE","genderBased":true,"minimumAge":"9 Years","maximumAge":"14 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Concentration (GMC) of Anti-HPV-16 Immunoglobulin G (IgG) Antibodies One Month After the Second Dose","description":"Anti-HPV-16 IgG antibodies were measured using HPV-16 virus-like particle (VLP) enzyme-linked immunosorbent assay (ELISA) one month after the second dose at the Frederick National Laboratory for Cancer Research in Frederick, Maryland, United States. The lower limit of quantitation of the HPV-16 assay was 1.41 international units (IU)/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1507.4","spread":null},{"groupId":"OG001","value":"2408.7","spread":null},{"groupId":"OG002","value":"3326.1","spread":null},{"groupId":"OG003","value":"1352.4","spread":null},{"groupId":"OG004","value":"2387.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentration of Anti-HPV-18 Immunoglobulin G Antibodies One Month After the Second Dose","description":"Anti-HPV-18 IgG antibodies were measured using HPV-18 VLP ELISA one month after the second dose at the Frederick National Laboratory for Cancer Research in Frederick, Maryland, United States. The lower limit of quantitation of the HPV-18 assay was 1.05 IU/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"382.7","spread":null},{"groupId":"OG001","value":"534.7","spread":null},{"groupId":"OG002","value":"535.2","spread":null},{"groupId":"OG003","value":"306.1","spread":null},{"groupId":"OG004","value":"379.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer (GMT) of Anti-HPV-16 Neutralizing Antibodies","description":"Anti-HPV 16 serum neutralizing antibodies were measured in a subset of participants by pseudovirion-based neutralization assay (PBNA) at the Frederick National Laboratory for Cancer Research in Frederick, Maryland, United States. The lower limit of quantitation of the HPV-16 PBNA was a titer of \\< 21.\n\nSamples were collected prior to the second dose and 1 month after the second dose for all treatment groups, and 18 months after the second dose for participants in Groups 1 and 4.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"104.0","spread":null},{"groupId":"OG001","value":"95.1","spread":null},{"groupId":"OG002","value":"125.7","spread":null},{"groupId":"OG003","value":"71.6","spread":null},{"groupId":"OG004","value":"125.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16790.9","spread":null},{"groupId":"OG001","value":"32019.5","spread":null},{"groupId":"OG002","value":"48615.4","spread":null},{"groupId":"OG003","value":"14281.3","spread":null},{"groupId":"OG004","value":"31459.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1541.9","spread":null},{"groupId":"OG003","value":"1368.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer (GMT) of Anti-HPV-18 Neutralizing Antibodies","description":"Anti-HPV 18 serum neutralizing antibodies were measured in a subset of participants by pseudovirion-based neutralization assay (PBNA) at the Frederick National Laboratory for Cancer Research in Frederick, Maryland, United States. The lower limit of quantitation of the HPV-18 PBNA was a titer of \\< 16.\n\nSamples were collected prior to the second dose and 1 month after the second dose for all treatment groups, and 18 months after the second dose for participants in Groups 1 and 4.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.9","spread":null},{"groupId":"OG001","value":"51.1","spread":null},{"groupId":"OG002","value":"77.9","spread":null},{"groupId":"OG003","value":"47.6","spread":null},{"groupId":"OG004","value":"55.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6081.5","spread":null},{"groupId":"OG001","value":"9303.8","spread":null},{"groupId":"OG002","value":"11205.3","spread":null},{"groupId":"OG003","value":"6774.4","spread":null},{"groupId":"OG004","value":"7548.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"441.7","spread":null},{"groupId":"OG003","value":"423.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroconversion Rate For HPV-16 One Month After the Second Dose","description":"Seroconversion rate is defined as the percentage of participants with a 4-fold rise in anti-HPV 16 IgG antibodies as measured by ELISA from baseline one month following the second dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroconversion Rate For HPV-18 One Month After the Second Dose","description":"Seroconversion rate is defined as the percentage of participants with a 4-fold rise from baseline in anti HPV-18 IgG antibodies as measured by ELISA one month following the second dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"GMC of Anti-HPV-16 IgG Antibodies One Month After the Second Dose: Comparison of Gardasil/Cecolin Mixed Dose With Gardasil 2-dose Regimen","description":"Anti-HPV-16 IgG antibodies were measured using HPV-16 VLP ELISA one month after the second dose at the Frederick National Laboratory for Cancer Research in Frederick, Maryland, United States. The lower limit of quantitation of the HPV-16 assay was 1.41 IU/mL.\n\nAnti-HPV-16 IgG GMCs measured 1 month after the second dose were compared between the Gardasil at Month 0 and Cecolin at 24 months two-dose regimen (Group 5) and the Gardasil at Month 0 and 6 two-dose regimen (Group 4).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1352.4","spread":null},{"groupId":"OG001","value":"2387.3","spread":null}]}]}]},{"type":"SECONDARY","title":"GMC of Anti-HPV-18 IgG Antibodies One Month After the Second Dose: Comparison of Gardasil/Cecolin Mixed Dose With Gardasil 2-dose Regimen","description":"Anti-HPV-18 IgG antibodies were measured using HPV-18 VLP ELISA one month after the second dose at the Frederick National Laboratory for Cancer Research in Frederick, Maryland, United States. The lower limit of quantitation of the HPV-18 assay was 1.405 IU/mL.\n\nAnti-HPV-18 IgG GMCs measured 1 month after the second dose were compared between the Gardasil at Month 0 and Cecolin at 24 Months two-dose regimen (Group 5) and the Gardasil at Month 0 and 6 two-dose regimen (Group 4).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"306.1","spread":null},{"groupId":"OG001","value":"379.0","spread":null}]}]}]},{"type":"SECONDARY","title":"GMC of Anti-HPV-16 IgG Antibodies 18-Months After Second Dose","description":"Anti-HPV-16 IgG antibodies were measured using HPV-16 VLP ELISA 18 months after the second dose for participants who received a 6-month dosing regimen (Groups 1 and 4) only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"138.5","spread":null},{"groupId":"OG001","value":"119.1","spread":null}]}]}]},{"type":"SECONDARY","title":"GMC of Anti-HPV-18 IgG Antibodies 18-Months After Second Dose","description":"Anti-HPV-18 IgG antibodies were measured using HPV-18 VLP ELISA 18 months after the second dose for participants who received a 6-month dosing regimen (Groups 1 and 4) only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.2","spread":null},{"groupId":"OG001","value":"23.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Solicited Adverse Events","description":"Solicited adverse events (AEs) were assessed by study staff 30 minutes after each vaccination and then daily for seven days after each vaccination by the participants using a memory aid.\n\nThe following specific solicited AEs were monitored for this trial:\n\n* Local Reactions:\n\n  * Pain, erythema/redness, swelling, induration, pruritus, abscess.\n* General/Systemic Reactions:\n\n  * Fever (oral or axillary temperature ≥ 38.0°C), headache, vomiting, nausea, fatigue, chills, muscle pain, cough, diarrhea, dizziness, allergic dermatitis, rash, syncope, and anorexia.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"12","spread":null},{"groupId":"OG004","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"10","spread":null},{"groupId":"OG004","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"131","spread":null},{"groupId":"OG001","value":"113","spread":null},{"groupId":"OG002","value":"106","spread":null},{"groupId":"OG003","value":"138","spread":null},{"groupId":"OG004","value":"120","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"59","spread":null},{"groupId":"OG002","value":"48","spread":null},{"groupId":"OG003","value":"76","spread":null},{"groupId":"OG004","value":"50","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Unsolicited Adverse Events","description":"Unsolicited AEs were any AEs reported spontaneously by the participant, identified during interview at study visits, observed by the study personnel during study visits or those identified during review of medical records or source documents. Unsolicited AEs were events occurring from the time of each study injection through approximately 30 days after each vaccination. Solicited AEs with onset after the solicitation period and through Day 30 post-vaccination were captured as unsolicited AEs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"46","spread":null},{"groupId":"OG003","value":"52","spread":null},{"groupId":"OG004","value":"34","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious Adverse Events (SAEs)","description":"An SAE was any AE that resulted in any of the following outcomes:\n\n1. Death\n2. Was life-threatening\n3. Required inpatient hospitalization or prolongation of existing hospitalization.\n4. Resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions.\n5. Congenital abnormality or birth defect.\n6. Important medical event that may not have resulted in one of the above outcomes but may have jeopardized the health of the study participant or (and) required medical or surgical intervention to prevent one of the outcomes listed in the above definition of SAEs.\n\nSAEs were collected from the time of first vaccination through the end of the study for each participant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"GMC of Anti-HPV-16 IgG Antibodies Prior to the Second Dose","description":"To evaluate the persistence of antibody responses to HPV after a single dose of vaccine, anti-HPV-16 IgG antibodies were measured using HPV-16 VLP ELISA immediately prior to the second dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":null},{"groupId":"OG001","value":"12.6","spread":null},{"groupId":"OG002","value":"12.0","spread":null},{"groupId":"OG003","value":"11.1","spread":null},{"groupId":"OG004","value":"10.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"GMC of Anti-HPV-18 IgG Antibodies Prior to the Second Dose","description":"To evaluate the persistence of antibody responses to HPV after a single dose of vaccine, anti-HPV-18 IgG antibodies were measured using HPV-16 VLP ELISA immediately prior to the second dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null},{"groupId":"OG001","value":"4.3","spread":null},{"groupId":"OG002","value":"4.4","spread":null},{"groupId":"OG003","value":"4.1","spread":null},{"groupId":"OG004","value":"3.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":205},"commonTop":["Vaccination site pain","Headache","Cough","Myalgia","Upper respiratory tract infection"]}}}